"Astellas" redirects here. For similar sounding terms, see Astelia, Astellia, Astell, Astelma, and Astala.
Astellas Pharma Inc.
Company type
Public (K.K)
Traded as
TYO: 4503
TOPIX Core 30 Component
TOPIX 100 Component
Nikkei 225 Component
Industry
Pharmaceutical
Predecessors
Yamanouchi Pharmaceutical Fujisawa Pharmaceutical (Merged in 2005)
Founded
1 April 2005; 19 years ago (2005-04-01)
Headquarters
2-5-1, Nihonbashi-Honcho, Chūō-ku, Tokyo 103-8411, Japan
Key people
Naoki Okamura (President and CEO) Kenji Yasukawa (Chairman of the Board)
Products
Prograf
Harnal
Vesicare
Funguard/Mycamine
Protopic
Xtandi
and other pharmaceuticals
Revenue
US$11,060,000,000 (FY 2013)
Net income
US$1,280,000,000 (¥1,139,000,000,000) (FY 2013)
Total assets
$14.86 billion (2016)[1]
Number of employees
17,217 (2016)[2]
Subsidiaries
Astellas US
Website
www.astellas.com/en/
Footnotes / references [3][4][5]
Astellas Pharma office in Canada
Astellas Pharma Inc. (アステラス製薬株式会社, Asuterasu Seiyaku Kabushiki-gaisha) is a Japanese multinational pharmaceutical company, formed on 1 April 2005 from the merger of Yamanouchi Pharmaceutical Co., Ltd. (山之内製薬株式会社, Yamanouchi Seiyaku Kabushiki-gaisha) and Fujisawa Pharmaceutical Co., Ltd. (藤沢薬品工業株式会社, Fujisawa Yakuhin Kōgyō Kabushiki-gaisha).
Astellas is a member of the Mitsubishi UFJ Financial Group (MUFJ) keiretsu.
^"Astellas Pharma on the Forbes Global 2000 List". Forbes.com. Retrieved 13 August 2018.
^"Corporate Information – Astellas Pharma Inc. GLOBAL WEBSITE". Astellas.com. Retrieved 13 August 2018.
^"Corporate Profile". Astellas Pharma. Archived from the original on August 14, 2012. Retrieved September 9, 2014.
^"Annual Report 2014" (PDF). Astellas Pharma. Archived from the original (PDF) on March 3, 2016. Retrieved September 9, 2014.
^"Astellas Pharma Snapshot". Bloomberg Businessweek. Retrieved January 25, 2015.
AstellasPharma Inc. (アステラス製薬株式会社, Asuterasu Seiyaku Kabushiki-gaisha) is a Japanese multinational pharmaceutical company, formed on 1 April 2005 from...
Astellas Institute for Regenerative Medicine is a subsidiary of AstellasPharma located in Marlborough, Massachusetts, US, developing stem cell therapies...
this source, which is in the public domain. "Astellas to Acquire Ogeda SA" (Press release). AstellasPharma. Archived from the original on 5 November 2021...
staphylococcus infections. In 2015, the company announced it would acquire AstellasPharmas dermatology business for $725 million. In 2018, the company acquired...
(PDF). AstellasPharma Inc. 31 March 2014. Archived from the original (PDF) on 4 September 2019. Retrieved 12 November 2016. "About Astellas". Astellas Pharma...
017. PMID 15261132. "CV Therapeutics and Astellas Announce FDA Approval for Lexiscan(TM)" (PDF). AstellasPharma US, Inc. "Rapiscan EPAR". European Medicines...
product pipeline includes enfortumab vedotin, being co-developed with AstellasPharma, tisotumab vedotin, being co-developed with Genmab, SGN-LIV1A, an ADC...
distribute the drug in Europe to Almirall and had licensed Asian rights to AstellasPharma. It was approved in the United States and in the European Union in...
pharmaceuticals and Fujisawa Pharmaceuticlas merged and were renamed as Astellas’ in 2005. Astellas gained FDA approval for Conivaptan hydrochloride on 29 December...
nonproprietary name. "Astellas' Vyloy (zolbetuximab) Approved in Japan for Treatment of Gastric Cancer" (Press release). AstellasPharma. 26 March 2024. Archived...
in adults and children. A branded version of the drug is owned by AstellasPharma, and is sold under the brand name Prograf, given twice daily. A number...
breakthrough therapy designation. The FDA granted the approval of Padcev to AstellasPharma US Inc. In July 2021, the FDA approved enfortumab vedotin for adults...
2009. "Teijin Pharma and AstellasPharma enter into agreement for marketing rights of TMX-67 in China and Hong Kong". First Word Pharma. 1 April 2010...
Drug Administration approved enzalutamide, developed by Pfizer and AstellasPharma for patients with castration-resistant prostate cancer. In August 2018...
mucormycosis, and invasive candidiasis. In 2014, Basilea and Astellas amended the agreement to give Astellas sole marketing authority in North America, and Basilea...
Yamanouchi, eponymous founder of Yamanouchi Pharmaceutical Co., now part of AstellasPharma Don Yamauchi, American chef Edwin M. Yamauchi, historian and biblical...
2011). "Astellas pulls the plug on darexaban". Pharmatimes. Archived from the original on 13 April 2014. Retrieved 11 April 2014. "AstellasPharma Inc. Discontinues...
hormone antagonist (GnRH antagonist) which was under development by AstellasPharma for the treatment of endometriosis and rheumatoid arthritis. It was...
and in India as Cednir by Abbott, Kefnir by Glenmark, Cefdair by Xalra Pharma and Cefdiel by Ranbaxy. Acylation of the primary amine 1 with 4-bromo-3-oxobutanoyl...
Russia and Iceland, it is marketed under the trade name Omnic by AstellasPharma Europe. The largest manufacturer of tamsulosin is Synthon BV (the Netherlands)...
of Vesicare LS was granted to AstellasPharma US, Inc. The INN is solifenacin. It is manufactured and marketed by Astellas, GlaxoSmithKline and Teva Pharmaceutical...
In 2006, Daiichi Sankyo acquired Zepharma, the OTC drugs unit of AstellasPharma. On June 10, 2008, the company agreed to take a majority (64%) stake...
Erlotinib, sold under the brand name Tarceva among others, is a medication used to treat non-small cell lung cancer (NSCLC) and pancreatic cancer. Specifically...
Dies in Trial of Astellas Gene Therapy Candidate". GEN - Genetic Engineering and Biotechnology News. Retrieved 2021-10-15. "Astellas Reports Update to...
it is a tyrosine kinase inhibitor. It was developed by AstellasPharma. In April 2018, Astellas filed a new drug application with the Food and Drug Administration...
1002/cmdc.201000259. PMID 20853390. S2CID 23228778. "Enzalutamide - AstellasPharma/Medivation - AdisInsight". Archived from the original on 17 July 2018...
Global Information
US$11,060,000,000 (FY 2013)